Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
12 studies found for:    Open Studies | "Hypereosinophilic Syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Hypereosinophilic Syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Condition: Hypereosinophilic Syndrome
Interventions: Drug: Mepolizumab 300 mg;   Drug: Placebo matching mepolizumab;   Drug: Active OCS capsules (5 mg prednisolone or prednisone);   Drug: Placebo matching OCS capsules
2 Recruiting Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Imatinib Mesylate
3 Recruiting Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Interventions: Drug: benralizumab;   Other: Placebo
4 Available This Record Contains Information About the Mepolizumab Compassionate Use Product Activities: 104317: An Open-Label Compassionate Use and Long-Term Access Study of Mepolizumab in HES 201956: A Long-term Access Programme for Subjects With Severe Asthma
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Mepolizumab
5 Recruiting Eosinophilia Diagnosis
Condition: Hypereosinophilic Syndrome
Intervention: Other: Scheduled exams and diagnosis
6 Recruiting Steroid Treatment for Hypereosinophilic Syndrome
Condition: Hypereosinophilia
Intervention: Drug: Corticosteroids
7 Recruiting Myeloproliferative Neoplasms (MPNs) Patient Registry
Conditions: Primary Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia;   Mastocytosis;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;   Leukemia, Myelomonocytic, Juvenile;   Chronic Eosinophilic Leukemia-not Otherwise Specified;   Myelodysplastic-Myeloproliferative Diseases;   Neoplasms;   Leukemia, Myelomonocytic, Chronic
Intervention: Other: Observational
8 Recruiting Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia
Intervention: Drug: eltrombopag olamine
9 Recruiting A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
10 Recruiting A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Condition: Eosinophils, Asthma
Intervention: Drug: reslizumab
11 Recruiting European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
Conditions: Lung Diseases, Interstitial;   Pulmonary Alveolar Proteinosis;   Pulmonary Eosinophilia;   Pulmonary Fibrosis;   Respiratory Distress Syndrome, Newborn;   Child
Intervention:
12 Recruiting Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
Condition: Severe Eosinophilic Asthma
Interventions: Drug: OC000459;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.